
Novartis will be highlighting data for its multiple sclerosis drug Gilenya at this year’s American Academy of Neurology (AAN) annual …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

